As shown by a previous analysis conducted on a large cohort of patients in the TRIBE study, those carrying relevant DPYD, and/or UGT polymorphisms experienced a higher rate of adverse events compared with the others, in particular G3-4 haematological adverse events, including neutropenia and FN.21 This evidence concerns the gene SLC35A2 and neutropenia.